Takeda Sued In U.S. For Failing To Report Actos Heart-Failure Cases
This article was originally published in PharmAsia News
Takeda Pharmaceutical’s U.S. unit is accused in a whistleblower suit of failing to report hundreds of congestive heart-failure incidents associated with its blockbuster Actos (pioglitazone).
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.